Assessing the safety and acceptability of psilocybin for Bipolar II depression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and acceptability of administering two sequential doses of 25 mg psilocybin, combined with therapeutic support, to patients with Bipolar II Disorder experiencing depression and suicidality. Participants will receive psychological support informed by mindfulness-based cognitive behavioral therapy (CBT) alongside the psilocybin treatment. The trial is non-randomized and will measure outcomes related to suicidality and depression using validated questionnaires at various time points. The goal is to determine if this approach can provide a feasible and effective treatment option for individuals with limited current options for managing their condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Must have completed written informed consent
* Must be at 25 years of age or older at screening (but below age of 70)
* Confirmed Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis of BD-II using clinical records and Diagnostic Interview for Anxiety, Mood, and Obsessive-compulsive disorder (OCD) and Related Neuropsychiatric Disorders (DIAMOND)
* Must meet criteria for suicidality according to the INQ cutoff scores: A score of at least 12 on the Perceived Burden (PB) subscale and at least a score of 36 on the Thwarted Belongingness (TB) subscale indicating substantial risk for passive suicidal ideation
* Must meet criteria for depression according to the MADRS cutoff scores: A score of 7-34 indicating mild to moderate depression
* Must pass medical examination (physical exam, personal/family medical history, including consultation with current medical provider, ECG, about 4 tablespoons blood draw, psychiatric/psychological assessments, urine drug test)
* Willingness to taper down mood stabilizers and other relevant medications (including but not limited to: antidepressants, antipsychotics, lithium, benzodiazepines, Monoamine oxidase inhibitors (MAOIs), Selective serotonin reuptake inhibitors (SSRIs), Serotonin and norepinephrine reuptake inhibitors (SNRIs), A serotonin-norepinephrine-dopamine reuptake inhibitors (SNDRIs), Tricyclic antidepressants (TCAs), stimulants, cannabis, and other medications, supplements or therapeutics that affect serotonergic function) for the duration of the study before and during administration days (starting 5 weeks before administration), and be off medication for at least 2 weeks prior to administration
* Willingness to stop allowed medication at least 24 h prior to administration of psilocybin as advised by study physician (e.g., benzodiazepines)
* Ability to complete all protocol required assessment tools without any assistance or alteration to the copyrighted assessments, and to comply with all study visits

Exclusion Criteria:

* Participants who do not read/speak English
* Active suicidal ideation with at least some intent and/or plan (i.e., a current score of 4 or 5 on the C-SSRS)
* History of medically significant suicide attempt in the last 6 months
* Current or past history of Bipolar I disorder, psychotic symptoms or psychotic disorder, (including but not limited to schizophrenia, delusional disorder, schizoaffective disorder) clinically relevant personality disorder (such as borderline, antisocial, narcissistic or paranoid personality disorder), or any serious psychiatric comorbidity considered negatively impacting participation or safety (e.g., PTSD or severe substance use or alcohol disorder) assessed by medical history and/or a structured clinical interview
* Have a first or second degree relative with Bipolar I disorder or a psychotic disorder
* Currently experiencing a hypomanic or mixed-symptom episode
* Have a psychiatric or other condition judged to be incompatible with establishment of rapport or safe exposure to psilocybin
* Any indication of a Personality Disorder (PD) such as but not limited to Borderline, Narcissistic, Antisocial, Paranoid, or Schizotypal PD based on Structured Clinical Interview for DSM-5 for PD and/or clinical judgment

Where it's running

• The University of Texas Health Science Center at Houston
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Thomas Meyer, PhD — The University of Texas Health Science Center, Houston
• Study coordinator: Thomas Meyer, PhD
• Email: thomas.d.meyer@uth.tmc.edu
• Phone: 713-486-2643

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Longitudinal look at how lasting TMS benefits can be predicted for depression

  This study follows people with major depressive disorder who responded to prior rTMS to see what factors predict how long their response lasts.

  Recruiting Hospital Center Guillaume Régnier · Rennes · NCT07684911

• Sleep health program for U.S. Marines

  This study will test whether different sleep health programs help active-duty U.S. Marines sleep better and reduce symptoms of depression, anxiety, PTSD, and suicidal thoughts.

  Recruiting Phase 2 San Diego State University · San Diego, California · NCT07420205

• See if suicidal behavior in kids during the Covid-19 period in the Auvergne-Rhone-Alpes region changed

  This study tests how common suicidal thoughts or actions were among children and teens in the Auvergne-Rhône-Alpes region during the COVID-19 period, using data from emergency departments and hospital records.

  Recruiting Hospices Civils de Lyon · Bron and 3 other locations · NCT07302295

• Personalized weight-loss medication plan for adults with bipolar disorder

  This pilot tests whether matching FDA-approved weight-loss medicines to specific obesity types helps adults aged 18–65 with bipolar disorder lose weight.

  Recruiting Phase 4 Mayo Clinic · Rochester, Minnesota · NCT07213466

• Digital twins to classify mental health patterns in adults with diabetes

  This project will try to create 'digital twin' profiles that combine glucose, mood, and behavior data to track mental health patterns in adults with diabetes.

  Recruiting Forschungsinstitut der Diabetes Akademie Mergentheim · Bad Mergentheim, Baden-Wurttemberg and 2 other locations · NCT07212075

• Personalized closed-loop deep brain stimulation for treatment-resistant Bipolar II depression

  This study will test a personalized closed-loop deep brain stimulation system to try to reduce depressive symptoms in adults with treatment-resistant Bipolar II disorder.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07127913

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.